FINWIRES · TerminalLIVE
FINWIRES

GM Korea's May Sales Decline 5.9% in May

By

GM Korea's domestic and overseas sales fell 5.9% year over year in May, according to a company release on Monday.

The company sold 47,081 vehicles in May, comprising 808 domestic sales and 46,273 overseas sales, the data showed.

The automotive company is now introducing monthly promotional campaigns to boost local sales, it said.

Related Articles

Asia

Bank of Shanghai Adjusts Conversion Price of 20 Billion Yuan Convertible Bonds

Bank of Shanghai (SHA:601229) adjusted the conversion price of its 20 billion yuan convertible bonds, according to a Shanghai bourse filing on Tuesday.The conversion price was adjusted to 8.35 yuan per share from 8.57 yuan per share, effective June 8, after the implementation of the 2025 profit distribution.

$SHA:601229
Asia

Carnaby Resources Strengthens Australia Project's Long-Term Production Profile, Says Euroz Hartleys

Carnaby Resources' (ASX:CNB) recent drill results "materially" strengthen the long-term production profile of the Greater Duchess copper-gold project, according to a Tuesday Euroz Hartleys note.The company said on Tuesday that it intersected 232 meters at 1.3% copper equivalent, including 65 meters at 2.9% copper equivalent, at the Miniboom Lode Discovery of its Greater Duchess Project in Queensland, Australia.The research firm noted that the company is looking to complete its feasibility study for the project mid-year, ahead of a final investment decision, and targeted first ore production in the second half of the year.Euroz Hartleys kept a speculative buy rating on Carnaby Resources while its price target of AU$0.96 is under review.The company's shares rose almost 9% to their highest since May 2024 on market close.

$ASX:CNB
Asia

Baiyunshan Pharmaceutical Gains China's Nod for Influenza Antiviral Suspension

Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) branch entity, Baiyunshan Pharmaceutical General Factory, received drug registration from China's medical products regulator for oseltamivir phosphate for oral suspension.The drug treats influenza A and B, according to a Tuesday filing with the Shanghai bourse.

$HKG:0874$SHA:600332